Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1. (currently amended): A compound ~~comprising~~ of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein

A is a zinc ligand or zinc ligand bearing moiety selected from the group consisting of:



B is  ~~or~~ absent ;

R is hydrogen or lower alkyl;

R_1 is hydrogen or lower alkyl;

R_2 is hydrogen, or lower alkyl;

R_3 is hydrogen or lower alkyl;

R_4 is lower alkyl, substituted lower alkyl, cycloalkyl-$(CH_2)_w$-, aryl-$(CH_2)_w$-, substituted aryl –$(CH_2)_w$- or heteroaryl-$(CH_2)_w$-;

R_5 is hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl-$(CH_2)_x$-, aryl-$(CH_2)_x$-, substituted aryl-$(CH_2)_x$-, or heteroaryl-$(CH_2)_x$-;

~~R_6 is hydrogen, R_7-CO-, or R_{12}-S-;~~

~~R_7 is alkyl, substituted alkyl, cycloalkyl-$(CH_2)_y$-, aryl-$(CH_2)_y$-, substituted aryl-$(CH_2)_y$- or heteroaryl-$(CH_2)_y$-;~~

R_8 and R_9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl-$(CH_2)_y$-, substituted aryl-$(CH_2)_y$-, heteroaryl-$(CH_2)_y$-,

 and ;

R_{10} is alkyl, substituted alkyl, cycloalkyl-$(CH_2)_y$, aryl-$(CH_2)_y$-, substituted aryl-$(CH_2)_y$- or heteroaryl-$(CH_2)_y$-;

~~R_{11} is hydrogen or lower alkyl;~~

~~R_{12} is alkyl, substituted alkyl, cycloalkyl-$(CH_2)_y$-, aryl-$(CH_2)_y$-, substituted aryl-$(CH_2)_y$-, heteroaryl-$(CH_2)_y$-,~~



~~in which case $-S-R_{12}$ completes a symmetrical disulfide;~~

R_{13} is hydrogen, lower alkyl, cycloalkyl or phenyl;

R_{14} is hydrogen, lower alkyl, lower alkoxy or phenyl;

R_{15} is lower alkyl or aryl-$(CH_2)_y$-;

D is –COOH~~, $-SO_2H$, $-SO_3H$, $-PO_3H_2$; $-OSO_3H$ or $-OPO_3H_2$~~;

E is hydrogen, ~~R_{12}~~, -COOH, $-CONH_2$, -CONH(lower alkyl), $-CON(\text{lower alkyl})_2$, $-CONH-(CH_2)_z$-aryl, $-CON(-(CH_2)_z\text{-aryl})_2$, -CO-amino acid, $-CH_2COOH$, CH_2OH, $-CH_2CH_2OH$, or $-COOR_{16}$;

R_{16} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl-$(CH_2)_y$-, substituted aryl-$(CH_2)_y$-, heteroaryl-$(CH_2)_y$-,



;

C is carbon;

H is hydrogen;

O is oxygen;

N is nitrogen;

S is sulfur;

P is phosphorus;

v is zero ~~or one~~;

w is zero or an integer ranging from 1 to 4;

x is an integer ranging from 1 to 4;

y is zero or an integer ranging from 1 to 6; and

z is zero, one, two, or three.

Claims 2-6 (canceled).

7. (original): The compound of claim 1, wherein R_1 and R_3, when v=0, are connected together to form an alkylene bridge of 3 carbon atoms representing with the carbon atoms to which they are attached a cyclopentane ring.

8. (original): The compound of claim 1, wherein R_1 and R_3, when v=0, are connected together to form an alkylene bridge of 4 carbon atoms representing with the carbon atoms to which they are attached a cyclohexane ring.

9. (canceled).

10. (original): The compound of claim 1, wherein R and R_4 are connected together to form an alkylene bridge of 3 carbon atoms representing with the nitrogen and carbon atoms to which they are attached a pyrrolidine ring.

11. (original): The compound of claim 1, wherein R and R_4 are connected together to form an alkylene bridge of 4 carbon atoms representing with the nitrogen and carbon atoms to which they are attached a piperidine ring.

Claims 12-15 (canceled).

16. (currently amended): The compound of claim 1, wherein the compound is further defined as: ~~N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-acetylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-propionylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-4-methyl-pentanoylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-methyl-butyrylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-hydroxy-2-mercapto-propionylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-hydroxy-2-mercapto-butyrylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-hexanoylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-4-phenyl-butyrylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-2-phenyl-acetylamino)-succinamic acid[[,]]; 3-(3-Biphenyl-4-yl-2-mercapto-propionylamino)-N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-succinamic~~

~~acid[[,]]; 3-(3-(4-Benzyloxy-phenyl)-2-mercapto-propionylamino)-N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-[3-(4-fluoro-phenyl)-2-mercapto-propionylamino]-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-[2-mercapto-3-(4-methoxy-phenyl)-propionylamino]-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-cyclohexyl-2-mercapto-propionylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-[3-(1H-indol-3-yl)-2-mercapto-propionylamino]-succinamic acid[[,]]; N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-naphthalen-2-yl-propionylamino]-succinamic acid[[,]]; N-(1-Carboxy-2-naphthalen-2-yl-ethyl)-3-(2-mercapto-3-phenyl-propionylamino)-succinamic acid[[,]]; N-(1-Carboxy-2-hydroxy-ethyl)-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic acid[[,]]; N-[1-Carboxy-2-(4-hydroxy-phenyl)-ethyl]-3-(2-mercapto-3-phenyl-propionylamino)-succinamic acid[[,]]; N-[1-Carboxy-2-phenyl-ethyl)-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic acid[[,]]; N-(2-Biphenyl-4-yl-1-Carboxy-ethyl)-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic acid[[,]]; N-(1-Benzyl-2-hydroxy-ethyl)-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic acid, N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-phenyl-propionylamino)-succinamic acid[[,]]; 4-[1-Carboxy-2-(1H-indol-3-yl)-ethylcarbamoyl]-4-(2-mercapto-3-phenyl-propionylamino)-ethyl]-butyric acid[[,]]; N-[2-(1H-indol-3-yl)-methylcarbamoyl-ethyl]-3-(2-mercapto-acetyl-amino)-succinamic acid[[,]]; N-[1-(1-Carboxy-2-hydroxy-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-phenyl-propionylamino)-succinamic acid[[,]]; N-[2-(1H-indol-3-yl)-methoxycarbonyl-ethyl]-3-(2-mercapto-acetyl-amino)-succinamic acid[[,]]; N-[2-(1H-indol-3-yl)l-ethyl]-3-(2-mercapto-3-phenyl-propionylamino)-succinamic acid~~[[,]]; 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid[[,]]; 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]; 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid[[,]]; 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid[[,]]; 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid[[,]]; 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]; 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid[[,]]; 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]; 4-Hydroxycarbamoyl-3-(5-

hydroxy-pentylcarbamoyl)-butyric acid[[,]]; 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]; ~~3-(2-Biphenyl-4-yl-ethylcarbamoyl)-5-hydroxycarbamoyl-pentanoic acid[[,]]~~; N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid[[,]]; or 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.

17. (currently amended): The compound of claim 16, wherein the compound is ~~further defined as~~ 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.

18. (original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a physiologically acceptable carrier or excipient.

19. (currently amended): The pharmaceutical composition of claim 18, wherein the compound ~~of claim 1~~ is further defined as: ~~a compound of claim 16~~ 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid; 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid; 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid; 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid; 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid; 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 4-Hydroxycarbamoyl-3-(5-hydroxy-pentylcarbamoyl)-butyric acid; 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid; N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid; or 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.

20. (currently amended): The pharmaceutical composition of claim 18, wherein the compound ~~of claim 1~~ is ~~further defined as the compound of claim 17 as~~ 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.

Claims 21-33 (canceled).

34. (new): The compound of claim 1, wherein A is



35. (new): The compound of claim 1, wherein A is



36. (new): The compound of claim 1, wherein A is



37. (new): The compound of claim 1, wherein A is



38. (new): The compound of claim 1 having the formula:



39. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.

40. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid.

41. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid.

42. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid.

43. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.

44. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.

45. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.

46. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(5-hydroxy-pentylcarbamoyl)-butyric acid.

47. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid.

48. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid.

49. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.